Roche Reports Phase 3 subgroup analysis Data for Alirocumab in Myasthenia gravis

Roche today announced Phase 3 subgroup analysis results for Alirocumab in patients with Myasthenia gravis. The study demonstrated that Alirocumab demonstrates durable complete remissions compared to standard of care or placebo. These results provide important insights into the treatment of Myasthenia gravis and support the continued development of Alirocumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Alirocumab was consistent with previous observations, with no new safety signals identified.